Safety and Long-term Outcomes of Defibrillator Therapy in Patients With Right-Sided Implantable Cardiac Devices in Adults With Congenital Heart Disease.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
03 2021
Historique:
received: 12 04 2020
revised: 22 05 2020
accepted: 30 05 2020
pubmed: 12 6 2020
medline: 1 7 2021
entrez: 12 6 2020
Statut: ppublish

Résumé

Implantable cardioverter-defibrillators (ICDs) have been proven to prevent sudden cardiac death in adult congenital heart disease (ACHD) patients. Although the left side is chosen by default, implantation from the right side is often required. However, little is known about the efficacy and safety of right-sided ICDs in ACHD patients. In this study we reviewed a total of 191 ACHD patients undergoing ICD/cardioverter resynchronisation therapy-defibrillator (CRT-D) implantation at our hospital between 2001 and 2019 (134 men and 57 women; age [mean ± standard deviation], 41.5 ± 14.8 years). Twenty-seven patients (14.1%) had right-sided devices. The most common causes of right-sided implantation were persistent left superior vena cava and vein occlusion (37.0%). Although procedure time (202.8 ± 60.5 minutes vs 143.8 ± 69.1 minutes, P = 0.008) was longer and the procedural success was lower (92.6% vs 99.4%, P = 0.008) for right-sided devices, no difference in R-wave and pacing threshold were noted. Among the 47 patients (24.6%) who underwent defibrillation threshold testing (DFT), no difference in DFT was observed (25.2 ± 5.3 J vs 23.8 ± 4.1 J, P = 0.460). During the median follow-up of 42.4 months, appropriate ICD therapy was observed in 5 (18.5%) and 30 (18.3%) patients for right- and left-sided ICDs/CRTDs, respectively (P = 0.978). No significant difference was seen in complications between them. Implantation of an ICD on the right side is technically challenging, but it is feasible as an alternative approach for ACHD patients with contraindications to left-sided device implantation.

Sections du résumé

BACKGROUND
Implantable cardioverter-defibrillators (ICDs) have been proven to prevent sudden cardiac death in adult congenital heart disease (ACHD) patients. Although the left side is chosen by default, implantation from the right side is often required. However, little is known about the efficacy and safety of right-sided ICDs in ACHD patients.
METHODS
In this study we reviewed a total of 191 ACHD patients undergoing ICD/cardioverter resynchronisation therapy-defibrillator (CRT-D) implantation at our hospital between 2001 and 2019 (134 men and 57 women; age [mean ± standard deviation], 41.5 ± 14.8 years).
RESULTS
Twenty-seven patients (14.1%) had right-sided devices. The most common causes of right-sided implantation were persistent left superior vena cava and vein occlusion (37.0%). Although procedure time (202.8 ± 60.5 minutes vs 143.8 ± 69.1 minutes, P = 0.008) was longer and the procedural success was lower (92.6% vs 99.4%, P = 0.008) for right-sided devices, no difference in R-wave and pacing threshold were noted. Among the 47 patients (24.6%) who underwent defibrillation threshold testing (DFT), no difference in DFT was observed (25.2 ± 5.3 J vs 23.8 ± 4.1 J, P = 0.460). During the median follow-up of 42.4 months, appropriate ICD therapy was observed in 5 (18.5%) and 30 (18.3%) patients for right- and left-sided ICDs/CRTDs, respectively (P = 0.978). No significant difference was seen in complications between them.
CONCLUSIONS
Implantation of an ICD on the right side is technically challenging, but it is feasible as an alternative approach for ACHD patients with contraindications to left-sided device implantation.

Identifiants

pubmed: 32522524
pii: S0828-282X(20)30517-1
doi: 10.1016/j.cjca.2020.05.038
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

407-416

Informations de copyright

Copyright © 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Satoshi Kawada (S)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Praloy Chakraborty (P)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Lisa Albertini (L)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Abhishek Bhaskaran (A)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Erwin N Oechslin (EN)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Candice Sliversides (C)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Rachel M Wald (RM)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

S Lucy Roche (SL)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Louise Harris (L)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Lorna Swan (L)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Rafael Alonso-Gonzalez (R)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Sara Thorne (S)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Eugene Downar (E)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Kumaraswamy Nanthakumar (K)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada.

Blandine Mondésert (B)

Department of Cardiology, Montreal Heart Institute, University of Montreal, Montreal, Québec, Canada.

Paul Khairy (P)

Department of Cardiology, Montreal Heart Institute, University of Montreal, Montreal, Québec, Canada.

Krishnakumar Nair (K)

University Health Network Toronto, Peter Munk Cardiac Centre and University of Toronto, Toronto, Ontario, Canada. Electronic address: krishnakumar.nair@uhn.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH